⌕
Alto Neuroscience · ANRO · NYSE
Tenet 52 · Mixed
Compare
$27.12−8.19%At closeTenet 52 · Mixed
$27.12−2.42 (−8.19%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD

Alto Neuroscience (ANRO) Stock

Alto Neuroscience (ANRO) closed at $27.12 on Nov 16, 2026; its Tenet Score is 52 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

43 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$27.12
Nov 16, 2026
Market cap
$1.2B
share price × the latest quarter's diluted weighted-average share count (vendor)
Tenet Score
52/100
Mixed · 313 Healthcare peers

Industry: Pharmaceutical Preparations

Alto Neuroscience Inc. scores 52/100. Mixed. Strongest on financial health, quality is the soft spot versus 313 Healthcare peers. Insufficient inputs: Tenet 52 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=313
52/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
54
Quality
17
Health
86
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth & Momentum omitted — no data yet.
ValueCQualityFHealthBGrowth—Momentum—
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
4.0×
price to book value
P/S
—
no P/S on file
ROE
−47%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
18.12
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file
52-wk range
—
no 52-week range on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Alto Neuroscience Inc.

We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Building on more than a decade of research by our founder, Dr. Amit Etkin, we…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 56 US ETFs · top wrappers by weightSee all ETFs holding ANRO →

Similar-sized companies in Pharmaceutical Preparations

The 5 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Alto Neuroscience in?

Alto Neuroscience is in the Healthcare sector and the Pharmaceutical Preparations industry.

What is Alto Neuroscience's Tenet Score?

Alto Neuroscience's Tenet Score is 52 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.